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Inhibition of PTP1B disrupts cell–cell adhesion and
induces anoikis in breast epithelial cells
Bylgja Hilmarsdottir1,2, Eirikur Briem1,3, Skarphedinn Halldorsson4, Jennifer Kricker1,3, Sævar Ingthorsson1,3, Sigrun Gustafsdottir1,3,
Gunhild M Mælandsmo2, Magnus K Magnusson1,3 and Thorarinn Gudjonsson*,1,3
Protein tyrosine phosphatase 1B (PTP1B) is a well-known inhibitor of insulin signaling pathways and inhibitors against PTP1B are
being developed as promising drug candidates for treatment of obesity. PTP1B has also been linked to breast cancer both as a tumor
suppressor and as an oncogene. Furthermore, PTP1B has been shown to be a regulator of cell adhesion and migration in normal and
cancer cells. In this study, we analyzed the PTP1B expression in normal breast tissue, primary breast cells and the breast epithelial cell
line D492. In normal breast tissue and primary breast cells, PTP1B is widely expressed in both epithelial and stromal cells, with highest
expression in myoepithelial cells and fibroblasts. PTP1B is widely expressed in branching structures generated by D492 when cultured
in 3D reconstituted basement membrane (3D rBM). Inhibition of PTP1B in D492 and another mammary epithelial cell line HMLE resulted
in reduced cell proliferation and induction of anoikis. These changes were seen when cells were cultured both in monolayer and in 3D
rBM. PTP1B inhibition affected cell attachment, expression of cell adhesion proteins and actin polymerization. Moreover, epithelial to
mesenchymal transition (EMT) sensitized cells to PTP1B inhibition. A mesenchymal sublines of D492 and HMLE (D492M and
HMLEmes) were more sensitive to PTP1B inhibition than D492 and HMLE. Reversion of D492M to an epithelial state using miR-200c-
141 restored resistance to detachment induced by PTP1B inhibition. In conclusion, we have shown that PTP1B is widely expressed in
the human breast gland with highest expression in myoepithelial cells and fibroblasts. Inhibition of PTP1B in D492 and HMLE affects
cell–cell adhesion and induces anoikis-like effects. Finally, cells with an EMT phenotype are more sensitive to PTP1B inhibitors making
PTP1B a potential candidate for further studies as a target for drug development in cancer involving the EMT phenotype.
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Protein tyrosine phosphatases (PTPs) and tyrosine kinases
modulate cellular levels of tyrosine phosphorylation and
regulate many cellular events such as differentiation, cell
growth, motility and proliferation.1 Regulation of the balance
between tyrosine phosphorylation and dephosphorylation
within cells is important for many cellular processes and
homeostasis and is implicated in a number of humandiseases.2
Protein tyrosine phosphatase 1B (PTP1B) is a 50 kDa non-
receptor phosphatase localized predominantly on the cyto-
plasmic surface of the endoplasmic reticulum, anchored via its
C-terminal region.3 PTP1B has a major role in downregulating
insulin and leptin signaling4 by dephosphorylating the insulin
receptor and thus terminating its signals. PTP1B-deficient
mice are hypersensitive to insulin and resistant to obesity
induced by a calorie-rich diet.5 For this reason, PTP1B has
received attention over the last few years as a novel
therapeutic target for the treatment of diabetes and obesity,
and as such there are numerous inhibitors against PTP1B at
various stages of development.6
In addition to insulin regulation, PTP1B also has a role in
other signaling pathways, such as growth factor and integrin
mediated processes, as well as cancer development.7,8
PTP1B is a major activator of Src by dephosphorylating the
inhibitory tyrosine phosphorylation site (Y529) on the COOH
terminus of the kinase.9 PTP1B has been shown to be a
positive mediator of the ErbB2-induced signals that trigger
breast tumorigenesis10,11 and to be required for ErbB2
transformation in breast epithelial cells through Src
activation.12 Substrate trapping and biochemical studies have
identified various substrates of PTP1B involved in cell
adherence and matrix attachment. For example, PTP1B
regulates the intracellular protein tyrosine kinases like focal
adhesion kinase (FAK), Src and adaptor proteins like
β-catenin and p130Cas.13–15 PTP1B has also been shown
to interact with integrin complexes and localize to early cell
matrix adhesion sites.3 Mouse fibroblasts, which expressed a
dominant-negative form of PTP1B have small matrix sites, are
impaired in cell spreading and show reduced Src activity.
Similarly, cells derived from PTP1B KO mice also show
defects in cell spreading.16 These data suggest that PTP1B is
an important regulator of integrin signaling pathways thereby
indicating a role in adhesion, spreading and formation of focal
adhesion.17 Developmental events underlying branching
morphogenesis in the breast are closely related to pathways
important for cancer progression, that is, epithelial plasticity
and epithelial–mesenchymal transition (EMT). EMT is a
process where epithelial cells lose epithelial characteristics
and gain mesenchymal traits. Although still debated, EMT is
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widely considered to be a key process in metastatic breast
cancer, which is the leading cause of cancer deaths.18 During
EMT, intracellular contacts change and during the transforma-
tion from a polarized epithelium to the mesenchymal state
there is loss of tight junctions and adhesion molecules.19 EMT
is believed to have an important role in cancer progression,
invasion, formation of metastasis and resistance to cancer
treatment.20 Thus, identification of drugs that specifically
target cells with the EMT phenotype, could be a key event to
improve cancer treatment.
In light of its central role in cell adhesion and Src regulation,
as well as its potential role in cancer, we sought to investigate
the impact of PTP1B inhibition on breast epithelial and
mesenchymal cells. Inhibiting PTP1B in D492 and HMLE,
breast epithelial cell lines, leads to apoptotic cell death with
morphological characteristics of anoikis, cell death induced by
loss of extracellular matrix attachment. PTP1B inhibition leads
to downregulation of cell adhesion proteins and disrupted actin
polymerization. In addition, we show that the transition from an
epithelial to amesenchymal state sensitizesmammary cells to
PTP1B inhibition, suggesting the therapeutic potential of
PTP1B inhibition in cancer treatment.
Results
PTP1B is ubiquitously expressed in normal human
breast tissue. PTP1B has in recent years been linked to
both tumorigenesis and tumor suppression21,22 but less is
known about its expression and function in the normal human
breast gland. Histochemical analysis of paraffin-embedded
breast tissue with antibodies against PTP1B and cell type-
specific markers, K14 (myoepithelial), K18 (luminal epithelial)
and vimentin (myoepithelial and fibroblasts), revealed that
PTP1B is, at least partially, co-stained with each of these
markers (Figure 1a). The expression intensity, however,
varied between different cell populations. Isolated cell
populations derived from reduction mammoplasty show that
PTP1B expression is enriched in myoepithelial cells and
fibroblasts (Figure 1b). Thus, PTP1B is ubiquitously
expressed in epithelial cells in the breast, as well as in
stroma.
PTP1B inhibition results in apoptosis of breast epithelial
cells. Given the ubiquitous expression of PTP1B in the
human breast gland, we examined if PTP1B had a role in
proliferation and survival of breast epithelial cells. D492 is a
breast epithelial cell line with stem cell properties that is able
to generate luminal and myoepithelial cells and generates
branching structures reminiscent of terminal duct lobular
units (TDLUs) when cultured in 3D reconstituted basement
membrane (3D rBM; Figure 3a). To test the effects of the
inhibition of PTP1B in D492, a specific PTP1B inhibitor
(IC50=8 μM) against the catalytic domain of the protein was
used. When cell growth and proliferation were analyzed,
PTP1B inhibition had a major effect on the survival of D492.
After 72 h of treatment with 16 μM of the PTP1B inhibitor, the
Figure 1 PTP1B is highly expressed in normal human breast tissue. (a) PTP1B is expressed both in the epithelial and stromal compartments of the breast.
Immunohistochemical stainings show prominent co-expression of PTP1B (red) and K14 (green) in myoepithelial cells (top row), PTP1B (red) and K18 (green) in luminal epithelial
cells (middle row), PTP1B (red) and vimentin (green) stains myoepithelial and fibroblasts (bottom row). Bar 100 μm. (b) PTP1B is predominantly expressed in myoepithelial cells
and fibroblasts in the breast gland. qPCR mRNA analysis shows that PTP1B expression is higher in myoepithelial cells (MEP) and fibroblasts than in luminal epithelial cells (LEP)
and endothelial cells (ENDO). Expression levels were normalized to GAPDH (upper). Western blot confirmed high expression of PTP1B in myoepithelial cells (lower). Actin was
used as a loading control
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majority of D492 cells were dead (Figure 2a, left). To estimate
the effect of PTP1B inhibition on the proliferation rate of D492
cells, we performed a cell tracing experiment using carboxy-
fluorescein succinimidyl ester (CFSE). CFSE is a fluorescent
membrane dye that measures cell proliferation by flow
cytometry. D492 cells were treated with either a DMSO
control or 8 μM of the PTP1B inhibitor. Flow cytometry
analysis of the CFSE-stained cells showed that 8 μM of
PTP1B inhibitor substantially reduced cell division of D492
cells opposed to the DMSO-treated cells (Figure 2a, right). To
further validate our findings, we tested the effect of PTP1B
inhibition on two additional cell lines, MCF10a and HMLE
(Supplementary Figures 1A and B). Treatment of both of
these cell lines with the PTP1B inhibitor resulted in severe
reduction of cellular growth and cell death, similar to what
was observed in D492 cells.
Annexin V apoptosis assay demonstrates that PTP1B
inhibition induces apoptosis in D492 (Figure 2b). In cells
treated with DMSO or a low concentration of the PTP1B
inhibitor (2 μM), only low levels of annexin V and propidium
iodide (PI) were detected. In contrast, when D492 cells were
treated with 8 μM of the PTP1B inhibitor, 26% of the cells were
annexin V positive and 21% PI positive, of which 15%
were stained for both markers. Annexin V/PI staining of cells
with increasing PTP1B inhibitor concentration demonstrates
several stages of programmed cell death, from early to late
apoptosis. The highest level of cell death was observed when
D492 cells were treated with 16 μM of the PTP1B inhibitor.
Annexin V/PI staining indicates that the cells are in late
apoptosis where 27% of cells stain positive for PI and only
12% are positive for annexin V. Interestingly, these apoptosis-
inducing effects were not seen if experiments were done
in medium containing serum or serum supplements
(Supplementary Figure 3) indicating that this inhibitor is not
effective in serum-containing media. To supplement our work
with the inhibitor, we also knocked down PTP1B using siRNA
(Figure 2d). This resulted in an inhibition of confluency,
whereby D492 cells treated with siRNA against PTP1B
demonstrated significantly less cell proliferation than cells
treated with negative control siRNA. Moreover, addition of
Figure 2 PTP1B is important for proliferation and survival of breast epithelial
cells. (a) Inhibition of PTP1B reduces cell division and affects survival of D492 cells.
Left cell survival assay reveals that PTP1B inhibitor causes reduction in proliferation
and cell death in D492. D492 were treated with DMSO (control) or 16 μM of a specific
PTP1B inhibitor for 3 days, stained with crystal violet and the optical density at
570 nm determined. All experiments were conducted in triplicate. Right, D492 cells
were stained with CFSE fluorescent dye, treated with DMSO or 8 μM of PTP1B
inhibitor and analyzed using flow cytometry over a period of 4 days. Note, reduced cell
division in D492 after PTP1B inhibition. (b) Inhibition of PTP1B results in apoptosis of
D492 cells. Annexin V and PI staining shows that PTP1B inhibitor induces apoptotic
cell death in D492. D492 cells were treated with DMSO (control) and various
concentrations of PTP1B inhibitor. (c) Cell death induced by the PTP1B inhibitor
shows the characteristics of anoikis. CPT induces classical apoptosis of D492 cells
over time in culture (middle column). D492 cells were treated with DMSO as a control
(left column). Treatment with PTP1B inhibitor results in failure of cells to establish a
confluent monolayer with a number of cells forming a rounded detached appearance
as in cells undergoing anoikis. (d) Knockdown of PTPN1 reduces proliferation of
D492 cells. D492 cells were transfected with siRNA PTPN1 s11507 or negative
control no. 1 siRNA at 50 nM and cell confluence was monitored for 72 h using
IncuCyte Zoom Live Cell Analysis System. Knockdown of PTPN1 resulted in an
inhibition of confluency, whereby D492 cells treated with siRNA against PTPN1
demonstrated significantly less cell proliferation than cells treated with negative
control siRNA. All experiments were done in triplicate
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serum did not rescue cell survival after PTP1B inhibition using
siRNA (Supplementary Figure 3b). These results indicate that
D492 cells are induced to undergo programmed cell death
after inhibition of PTP1B, whether it is via a small molecule
inhibitor or siRNA knockdown of PTP1B.
The classical morphology of a cell going through apoptosis
is nuclear fragmentation, cell shrinkage and membrane
blebbing.23 The observed morphology of cells after treatment
with the PTP1B inhibitor was not consistent with these
hallmarks of apoptosis. To compare the morphology of cells
undergoing classic apoptosis and cell death induced by
PTP1B inhibition, D492 cells were treated with 10 μM
camptothecin (CPT), an apoptosis inducer alongside the
PTP1B inhibitor. Cells treated with CPT show typical
apoptosis morphology (Figure 2c and Supplementary Video
File 1), whereas cells treated with the PTP1B inhibitor appear
round and surrounded by a halo as they detach from the
surface. This morphology is consistent with cells undergoing
anoikis, programmed cell death induced by detachment from
the extracellular matrix.24–26
Inhibition of PTP1B in D492 cells results in disturbed
morphogenesis suggesting anoikis. D492 cells generate
in vivo-like branching structures in 3D cell culture (Figure 3a,
top). Analysis of PTP1B expression in these branching
structures revealed similar widespread expression as in the
normal breast gland with increased intensity at the lobular
ends (Figure 3a). F-actin is a cytoskeletal protein that is
expressed equally throughout the structure, whereas β4-
integrin is localized at the surface of the structure in contact
with the basement membrane.
D492 branching structures were treated with the 32 μM of
the PTP1B inhibitor, or 20 μM of CPT as control for 48 h.
Figure 3b (see also Supplementary Video File 2) shows that
while CPT induces cell blebbing, shrinkage and accumulation
of cell debris surrounding the structure, the PTP1B inhibitor
induces loss of cell–cell contact and the branching structure
shows a ‘grape-like’ morphology where cells do not move
synchronically within the structure (as in the control), but rather
individually.
In-gel immunostaining of treated branching structures
shows that only CPT treatment induces cleaved caspase-3
staining (Figure 3c). Staining for of F-actin is diminished in
structures treated with PTP1B inhibitor compared with DMSO
treatment.
Src activity in D492 cells is dependent on PTP1B. Src
activity is regulated by phosphorylation of two distinct
tyrosine residues, autophosphorylation of Tyr416 in the kinase
domain activates Src whereas phosphorylation of Tyr529 in
the C-terminal tail inactivates it. Consequently, activation of
Src requires the removal of the C-terminal phosphate by
specific PTPs. To assess the effect of PTP1B inhibition on
Src phosphorylation in D492 cells, we treated the cells with
various concentrations of the PTP1B inhibitor for 48 h
followed by protein isolation for western blot analysis. The
phosphorylation level at Tyr529 was determined using a
phosphospecific antibody as shown in Figure 4. Treatment of
D492 cells with the PTP1B inhibitor caused a significant
increase in Tyr529 phosphorylation (Figure 4a).
Phosphorylation on the inhibitory tyrosine increased gradu-
ally with increased concentration of the inhibitor. To support
this finding, D492 cells were treated with DMSO or
16 μM of the PTP1B inhibitor for 3 h. The cells were then
fixed with methanol and stained for PTP1B and pSrc
Tyr529. The phosphorylation status of Src had increased
drastically and appeared to reside at the cell membrane
(Figure 4a, right).
To confirm that the PTP1B inhibitor is working directly on
PTP1B interactions with substrate proteins, we used
proximity ligation assay (PLA), which detects localization of
protein interactions within the cell. Using antibodies detecting
EGFR and Src (known PTP1B substrates),27,28 and PTP1B we
observed a loss of signalwhen cellswere treatedwith the inhibitor
(Figure 4b, left). Each dot represents colocalization between
PTP1BandSrc andPTP1BandEGFR, respectively. The ImageJ
(NIH, USA) program was used to quantify the number of dots in
non-treated versus treated cells (Figure 4b, right).
PTP1B inhibitor induces loss of adhesion molecules in
D492. To investigate how PTP1B inhibition affects cell
adhesion, we used a cell detachment assay where cells
were treated with 8 or 16 μM of the PTP1B inhibitor, 10 μM of
CPTor DMSO as control for 24 h (Figure 5a). After treatment,
cell attachment to the culture plate was measured as cells
detached after 1 min of trypsinization compared with total
number of cells. PTP1B-treated cells were much more
sensitive to trypsinization than control cells. In contrast,
induction of apoptosis with CPT did not facilitate detachment
from the culture plate.
To further confirm our hypothesis that the PTP1B inhibitor is
affecting cell adhesion, we treated D492 cells with different
concentrations of the PTP1B inhibitor and tested the expres-
sion of selected adhesion molecules by western blot
(Figure 5b). At the highest concentration of the inhibitor, cells
lost the expression of claudin-1, FAK and E-cadherin, whereas
occludin expression remained unchanged. Moreover, phalloi-
din staining shows that actin polymerization in D492 cells is
completely abolished after treatment with the PTP1B inhibitor
(Figure 5c), whereas total actin levels are unaffected
(Figure 5b). To supplement this data, we treated HMLE cells
with various concentration of the inhibitor for 48 h and tested
the expression of E-cadherin, FAK and pFAKY925 (Supple-
mentary Figure 4). Western blot analysis shows diminished
expression of E-cadherin in HMLE cells treated with 16 μM of
the PTP1B inhibitor, reduced expression of FAK and loss of
FAK phosphorylation.
EMT sensitizes cells to loss of attachment caused by
PTP1B inhibition. During EMT, epithelial cells loose cell–
cell adhesion and gain increased migratory and invasive
properties. To test the effect of the PTP1B inhibitor on less
adherent cells than D492, we used D492M, a mesenchymal
subline of D492. D492M is ideal to use as a comparison as it
is directly derived from D492 and has all the characteristics of
a cell line that has gone through EMT.29
D492M has a mesenchymal phenotype, is more mobile and
has reduced attachment to the culture flask compared with
D492. We compared the effects of the inhibitor on D492 and
D492M using a crystal violet survival curve. Importantly, this
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assay does not assess cell death, but how many cells are
attached to the culture flask surface in each measured time
point. Figure 6a shows a significantly reduced cell count in
D492M compared with D492, and thus, an increased effect of
the PTP1B inhibitor. To show that the increased effects of
PTP1B inhibition on mesenchymal cells are not cell line
specific, we used the human mammary cell line HMLE30 and
its mesenchymal derivative HMLEmes. The mesenchymal-
derived cells were made by sorting for the EpCAM-negative
population of the HMLE cell line. HMLEmes show classical
characteristics of EMT in gene expression and morphology
(unpublished data). As with the D492 cell lines, HMLE and
HMLEmes are not cultured in the presence of serum.
Similar to D492/D492M, the mesenchymal cell line HMLEmes
also proved to be more vulnerable to PTP1B inhibition
than the epithelial HMLE cell line, indicating that cells with a
mesenchymal phenotype and less expression of cell
adhesion molecules are more sensitive to PTP1B inhibition
(Figure 6b).
We have previously shown that overexpression of
miR-200c-141 in D492M induces mesenchymal to epithelial
transition (MET).31 To analyze if MET makes cells more
resistant to cell death after PTP1B inhibition, we used a cell
detachment assay to compare the differences between
D492MCtrl and D492MmiR-200c-141 with regard to trypsinization.
Figure 6c shows that D492MCtrl is more sensitive to
trypsinization after treatment with the PTP1B inhibitor than
its epithelial subline, D492MmiR-200c-141.
Figure 3 Inhibition of PTP1B affects branching morphogenesis and induces anoikis-like effects in D492 cells cultured in 3D. (a) Expression of PTP1B in TDLU-like structures
generated by D492 cells in 3D culture. (A) D492 cells form branching structures when cultured in 3D rBM matrix. (B) Expression of F-actin (green), PTP1B (red) and (C)
expression of β4-integrin (green) and PTP1B in D492 cells cultured in 3D rBM. Note, the strong expression of PTP1B at the lobular ends. Bar 50 μm. (b) Inhibition of PTP1B
induces loss of cell adhesion in 3D structures. D492 cells cultured in 3D rBM were treated with 10 μM of CPT, 32 μM of the PTP1B inhibitor or DMSO as control for 48 h. (c) D492
cells treated with PTP1B inhibitor die by anoikis. D492 cells treated with the PTP1B inhibitor do not show staining for cleaved caspase 3 in 3D culture (green). CPTwas used as a
positive control for apoptosis, arrows point to cells positive for cleaved caspase 3. Phalloidin stains F-actin (red). DAPI was used for nuclear staining (blue)
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Figure 4 PTP1B inhibitor decreases Src activation in D492 cells. (a) Treatment with PTP1B inhibitor results in increased phosphorylation of the inhibitory SrcY529. Left,
western blot analysis of pSrcY529 shows that PTP1B inhibitor increases phosphorylation of pSrcY529. Protein extracts from D492 cells after treatment with DMSO and various
concentrations of PTP1B inhibitor for 48 h. GAPDH as loading control. Right, Immunofluorescence staining of pSrc in D492 cells treated with the PTP1B inhibitor confirms
increased phosphorylation of pSrcY529 after PTP1B inhibition. pSrc (green), PTP1B (red), TOPRO-3 nuclear staining (blue). Bar 20 μm. (b) Inhibition of PTP1B disrupts PTP1B
protein interactions. PLA shows that PTP1B complexes with Src (left) and EGFR (right) (green arrows) are disassembled (left). DAPI nuclear stain (blue). Cell profiler was used to
quantify frequency of positive puncta per cell (right)
Figure 5 PTP1B inhibition affects expression of cell adhesion molecules and actin polymerization. (a) D492 cells treated with PTP1B inhibitor show loose surface attachment.
D492 cells were treated with 8 or 16 μM of the PTP1B inhibitor, 10 μM of CPT or DMSO as control for 24 h, and assayed for sensitivity to trypsinization. (b) Expression of
various cell adhesion molecules is reduced in D492 cells after PTP1B inhibition for 48 h. D492 cells were treated with various concentrations of the PTP1B inhibitor for 48 h
followed by protein isolation. Claudin-1, FAK and E-cadherin expression is lost when treated with 16 μM of the inhibitor. PTP1B inhibition does not affect occludin,
β-catenin and actin expression. (c) F-actin polymerization is lost in D492 cells treated with inhibitor for 5 h. Phalloidin stains F-actin (green), Concavalin A stains endoplasmic
reticulum (red)
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Collectively, we have shown that breast epithelial cellswith a
mesenchymal phenotype are more sensitive to PTP1B
inhibition than their epithelial counterparts.
Discussion
In this work, we have studied the expression of PTP1B in
human breast tissue and human breast epithelial
progenitor cells. We have furthermore analyzed its role in cell
proliferation and survival of breast epithelial cells in culture.
PTP1B expression is abundant in primary human breast
tissue with highest expression in primary basal/myoepithelial
cells and fibroblasts. Expression of PTP1B is also high in D492
cells grown in 3D rBM where staining is increased at lobular
ends of the branching structures. Inhibition of PTP1B via a
specific PTP1B inhibitor or by siRNA knockdown of PTP1B
resulted in marked effects on the survival of D492 cells by
inducing cell death. Our data based on CFSE staining further
indicates that the cell death in D492 is primarily in dividing
cells. Furthermore, there were striking changes in the cell
morphology during PTP1B inhibitor treatment; the cells
were round with characteristics of reduced cell attachment
and spreading. Collectively from these changes, we
conclude that inhibition of PTP1B in D492 cells results
in loss of cell attachment and cell death in the form of anoikis.
In the current work, we have exclusively focused on in vitro
models. Culturing cells in 3D rBM can capture morphogenesis
seen in vivo but will never fully replace in vivo models.
Therefore, it will be important to continue this work using
in vivo models.
Our results in the breast gland are consistent with other
publications where PTP1B inhibition resulted in apoptosis in
non-small cell lung cancer cells22 and susceptibility to
anoikis in colorectal cancer cells.32 We show here that the
cell death induced by inhibition/knockdown of PTP1B and
CPT-induced apoptosis demonstrates morphology represen-
tative of anoikis and classical apoptosis, respectively. We also
provide evidence that PTP1B can activate Src, a well-known
oncogene, which is known to have a role in anoikis.33,34
Furthermore, PTP1B inhibition results in downregulation
of the adhesion molecules claudin-1, E-cadherin and FAK
and disrupted actin polymerization. Interestingly, mesenchy-
mal derivatives of mammary epithelial cells (both D492M
and HMLEmes) are more sensitive to PTP1B inhibition than
the epithelial cell lines. Moreover, a MET cell line,
D492MmiR-200c-141 is more resistant to PTP1B inhibition than
the control cell line. These data are particularly interesting
because cells that have undergone EMT, especially cancer
cells, are in general more resistant against drug treatment. If
inhibition of PTP1B renders these cells more vulnerable for
induction of cell death, this could open up possibilities of
using PTP1B inhibitors in therapy against a subset of breast
cancer tumors, namely those enriched with cells showing
an EMT phenotype.
Anoikis resistance of tumor cells constitutes an essential
event in tumor progression to metastases in carcinomas.35
The metastatic process involves the detachment of
adherent cancer cells, invasion into the surrounding
stroma and extravasation of the metastatic cells into vascular
vessels. Anchorage-independent cells then travel to distant
organs where they can colonize and form metastasis.
Studies of anoikis and the characterization of the mecha-
nisms mediating sensitivity to anoikis can provide important
insights into epithelial homeostasis and metastasis. Src
tyrosine kinase is one of the key molecules believed to have
a critical role in the development of resistance against anoikis.
Studies have shown that Src overexpression significantly
contributes to resistance of epithelial cells to anoikis.36,37
Src is a powerful oncogene but it is rarely mutated in
human cancer, suggesting that it is involved in later stages
of carcinogenesis and has a supporting, rather than an
initiating role.38 In human breast cancer, Src activity is often
increased 4- to 30-fold compared with activity in normal breast
tissue and it has also been reported that Src protein levels can
be increased in breast cancer.39 Numerous studies have
shown that elevated catalytic activity of Src is required to
confer resistance to cell death, thus identifying Src as a
survival factor that protects cancer cells from apoptosis and
anoikis.40,41
Studies indicate that PTP1B is the primary PTP capable
of dephosphorylating c-Src in breast cancer cell lines
and thus controlling its kinase activity.42 Our findings
suggest that when D492 cells are treated with the PTP1B
inhibitor Src activity is diminished, identifying PTP1B
as a positive regulator of Src. Western blotting showed
that PTP1B inhibition enhanced phosphorylation on the
tyrosine inhibitory phosphorylation site in Src. This finding
was further confirmed by staining cells with a Src-phospho-
specific (Y529) antibody, where D492 cells treated with
PTP1B inhibitor showed increased Y529-phosphorylated
Src at the cell membrane, as well as in the cytoplasm. This
staining correlates with reported Src localization in other
studies.12
In this study, we also show that inhibiting PTP1B
downregulates adhesion signaling. Thus, PTP1B inhibition
could interfere with the cancer cells abilities to reside in a
secondary site. Importantly, the mesenchymal D492M cell line
is more sensitive to PTP1B inhibition than D492. Mesenchy-
mal cells are characteristically less sensitive to apoptosis
and many chemotherapeutic agents.43,44 Mesenchymal
cells are furthermore less adhesive. We suggest that under
these circumstances of low adhesion, the mesenchymal
cells rely on Src activity to prevent anoikis. As PTP1B
inhibition leads to reduced Src activity, this may explain the
sensitivity of the mesenchymal cells to the inhibitor. These
findings suggest a therapeutic role for PTP1B inhibition to
target mesenchymal derivatives of cancer cells, cells that are
usually less likely to be targeted by conventional
chemotherapeutics.
Collectively, our data have relevance regarding PTP1B in
normal cell biology and cancer biology. We have shown that
PTP1B may have an important role in cell adhesion and
anoikis. PTP1B has been studied intensively as a drug
target for type-2 diabetes, and already there are several
inhibitors in clinical trials. Our data suggest that these
inhibitors could also have a therapeutic role in cancer,
specifically targeting cells that rely on Src-mediated ancho-
rage independence.
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Materials and Methods
Cell culture. D492 and D492M were cultured in the chemically defined medium
H14 (ref. 45) unless indicated otherwise. HMLE and HMLEmes cells were grown in
DMEM/F-12 medium supplemented with 10 ng/ml EGF, 10 μg/ml insulin and 0.5 μg/
ml hydrocortisone. HMLEmes cells were generated by sorting and collecting an
EpCAM-negative population from HMLE cells. HMLE cells were used with the
permission from Dr. Robert Weinberg. MCF10a were cultured in H14 medium. All
cell lines were routinely authenticated with genotype profiling.
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Primary endothelial cells were isolated as previously described46and cultured in
EBM basal medium (Lonza, Walkersville, MD, USA), containing 50 IU/ml penicillin
and 50 μg/ml streptomycin. The EBM medium was supplemented with 5% FBS.
Primary luminal epithelial cells were cultured in the chemically defined medium
CDM3.47 Primary myoepithelial cells were cultured in the chemically defined medium
CDM4.48 For 3D cultures, 10 000 D492 cells were plated separately inside
reconstituted basement membrane matrix, rBM (Matrigel, Becton Dickinson, Franklin
Lakes, NJ, USA). Experiments were carried out in 24-well dishes (Falcon, Corning
brand, NY, USA) using 300 μl Matrigel, in which single cells were suspended.
For staining of 3D structures, the Matrigel was dissolved with Matrigel lysis buffer
on ice at mild rotation for 20–60 min. Branching structures were then spun down in a
pre-cooled rotor at 1000 r.p.m. for 5 min at 2 °C. The structures were then
resuspended in 30 μl PBS and left to dry on glass slides.49
Materials. PTP1B inhibitor50 was purchased from Calbiochem; EMD Millipore
brand, Billerica, MA, USA (#539741) and CPT from Sigma (St. Louis, MO, USA)
(#C9911). PTP1B rabbit polyclonal antibody was purchased from R&D Systems
(Minneapolis, MN, USA) and PTP1B mouse IgG1 antibody was purchased from BD
Bioscience (Fisher Scientific brand, Waltham, MA, USA), Src (phospho Y529), actin,
GAPDH and K14 antibodies were purchased from Abcam (Cambridge, UK). K18
and vimentin were purchased from DAKO (Agilent brand, Santa Clara, CA, USA)
and β4-integrin was from Sigma-Aldrich (St. Louis, MO, USA). F-actin was stained
with conjugated phalloidin (Invitrogen, Carlsbad, CA, USA). Isotype-specific
secondary antibodies were from Invitrogen as well as TOPRO-3 nuclear
counterstain. Specimens were visualized on a Zeiss LSM 5 Pascal laser-
scanning microscope (Carl Zeiss, Germany) and Olympus FluoView 1200 (Japan).
qRT-PCR. Total RNA was extracted with Tri-Reagent (Ambion, Thermo Scientific
brand, Waltham, MA, USA). The RNA was DNAase treated and reverse transcribed
with hexanucleotide primers using Supercript II and Superscript IV (ThermoFisher,
Waltham, MA, USA). Resulting cDNA was used as template for qPCR. Primer pairs
and probes from Applied Biosystems (Foster City, CA, USA) (TaqMan) were used
for PTPN1 (HS00182260_m1) and GAPDH (4326317E) as an endogenous
reference gene.
PTPN1 knockdown. D492 cells were transfected with Silencer Select
pre-designed siRNAs (Ambion, silencer select negative control no. 1 siRNA,
silencer select validated siRNA PTPN1 s11506, silencer select validated siRNA
PTPN1 s11507 and silencer select validated siRNA PTPN1 s11508). Transfections
were done according to the manufacturer´s protocol using Lipofectamine RNAiMAX
(Invitrogen, cat. 13778030) in 24-well plates (Corning, New York, USA, cat. 353047).
RNA was extracted using Tri-Reagent solution (Ambion, cat. AM9738) according to
the manufacturer’s protocol. RNA was reverse transcribed using SuperScript IV
Reverse Transcriptase (Invitrogen, cat. 18090050) and expression of PTP1B was
assayed on Applied Biosystems 7500 Real-Time PCR System using TaqMan Gene
Expression Assays Hs00942477 for PTPN1 and Hs99999905 for GAPDH as a
control. Cell proliferation was assayed using IncuCyte Zoom Live Cell Analysis
System, Essen Bioscience, Ann Arbor, MI, USA.
Western blot analysis. Protein lysates were acquired using RIPA lysis buffer
supplemented with both phosphatase and protease inhibitor cocktails (Life
Technologies, Thermo Fisher Scientific brand, Waltham, MA, USA). Equal amounts
(5 μg) of proteins in RIPA buffer were separated on 10% NuPage Bis-Tris gels
(Invitrogen) and transferred to a PVDF membrane (Invitrogen). Antibodies used are
as follows: E-Cad (BD), PTP1B (BD, Fisher Scientific brand, Waltham, MA, USA),
pSrc529 (Abcam), claudin-1 (Zymed, San Francisco, CA, USA), occludin (Zymed),
β-catenin (Biolegend, San Diego, CA, USA), FAK (Cell Signaling, Danvers, MA,
USA), pFAK (Cell Signaling) GAPDH (Abcam) and actin (Abcam) were used. In
Figures 1,4 and 5, secondary antibodies were horsesadish peroxidase-conjugated
anti-mouse or rabbit (BD Scientific; Fisher Scientific brand, Waltham, MA, USA)
used at dilution 1:10 000. The protein bands were visualized using enhanced
chemiluminescence (ECL) system (Thermo Scientific, Waltham, MA, USA). In
Supplementary Figure 4, secondary antibodies were mouse or rabbit IRDye (Li-Cor,
Lincoln, NE, USA) used at 1:10 000 and protein bands were detected using the
Odyssey Infrared Imaging System (Li-Cor) and then fluorescent images were
converted to gray scale.
All western blots are representative of three separate experiments.
Cell growth curve with PTP1B inhibitor. D492 cells were seeded at
70% confluency per well in a 24-well plate in growth media. One day after
seeding, the medium was replaced with H14 medium and treated with either
DMSO or the indicated concentration of inhibitor. For each time point,
cells were fixed with 250 μl of crystal violet solution (0.25% crystal violet
in 20% methanol). Fixed cells were then incubated in 500 μM lysis
solution (33% acetic acid) for 10 min. To quantitate the amount of crystal violet
in each sample, the optical density at 570 nm was determined using a
spectrophotometer.
Apoptosis assay. Analysis of annexin V/PI binding was determined using an
Annexin V-FITC apoptosis Detection Kit I (BD Pharmingen, Becton Dickinson brand,
Franklin Lakes, NJ, USA). The D492 cell line was treated with DMSO or indicated
concentrations of PTP1B inhibitor for 48 h. Cells were harvested and resuspended
in binding buffer at a concentration 1 × 106 cells/ml. Later, 2.5 μl of Annexin V were
added to 100 μl of suspension and incubated at RT in the dark for 15 min. In all,
400 μl of 1 × binding buffer were added to each tube and 2.5 μl of PI just before
10 000 cells from each tube were analyzed in a FACSCalibur, BD Bioscience. Data
were processed using FCSexpress (De novo software, Los Angeles, CA, USA).
CFSE-based cell proliferation. Proliferation was assessed with a CellTrace
CFSE Proliferation Kit – for flow cytometry (Invitrogen). D492 cells were
resuspended in 1 ml PBS with 0.1% BSA at 1 × 106 cells/ml and CFSE dye
added to the cells in a final concentration of 0.5 μM. The cells were incubated
in a water bath at 37 °C for 10 min, 10 ml of FBS was added to stop the reaction
and the cells resuspended in 1 ml of normal growth media and seeded in
a 24-well plate. PTP1B inhibitor at a final concentration of 8 μM or equivalent
amount of DMSO was added to the cells. The dilution of CFSE was measured
by counting 10 000 viable cells with FACSCalibur (BD Bioscience) for 4
consecutive days.
In situ PLA. Colocalization analysis of PTP1B interactions with substrate
proteins was studied using a PLA using the Duolink(R) kit (Olink Bioscience, Sigma,
St. Louis, MO, USA). D492 cells were treated with 32 μM of the PTP1B inhibitor for
5 h, fixed with 4% formaldehyde, blocked and incubated with primary antibodies in
two different combinations: PTP1B mouse (BD, #610139) with Src rabbit (Cell
Signaling, #2109) and PTP1B rabbit (R&D Systems, AF1366) with EGFR mouse
(BD, #555996) overnight, followed by a standard PLA protocol according to the
manufacturer's instruction. Nuclei were counterstained with DAPI and
specimens were visualized on a Olympus FluoView 1200. For quantification of
PLA signal, ImageJ was used to quantify the number and area of the Duolink
puncta, and for all experiments quantifications were performed from at least
three images.
Live cell imaging. D492 cells were seeded directly onto eight-well chamber
slides, or embedded in Matrigel and seeded into eight-well chamber slides (BD) at
densities of 3000 cells per well in 100 μl Matrigel. After 10 days in culture in a
standard incubator, the chamber slide was removed from the incubator, treated with
Figure 6 Cells with mesenchymal phenotype are more sensitive to PTP1B inhibition than their isogenic epithelial counterparts. (a) D492M is more sensitive toward PTP1B
inhibition than D492. The isogenic cell lines D492M and D492 that show mesenchymal and epithelial phenotype, respectively, were treated with DMSO (control) or 16 μM of a
specific PTP1B inhibitor for 3 days. Cells were stained with crystal violet at different time points and optical density measured at 570 nm to evaluate the survival of cells. Note how
D492M cells show lesser survival than D492. All experiments were conducted in triplicate. (b) HMLEmes is more sensitive to PTP1B inhibition than HMLE. HMLE and HMLEmes
were treated with DMSO (control) or 16 μM of a specific PTP1B inhibitor for 3 days, stained with crystal violet and the optical density at 570 nm determined. (c) MET reverses
sensitivity to PTP1B inhibition in D492M. D492MCtrl (mesenchymal) and D492MmiR-200c-141 (epithelial) were treated with 16 μM of the PTP1B inhibitor or DMSO as control for 24 h
and assayed for sensitivity to trypsinization
PTP1B inhibition induces anoikis in breast cells
B Hilmarsdottir et al
9
Cell Death and Disease
the relevant inhibitor and transferred to an automated inverted microscope (Leica
DMI 6000B, Germany) equipped with an environmental chamber, temperature
control module and CO2 regulator (Pecon, Germany). Images were taken through a
20x objective with a CCD camera (Exi Blue, QImaging, Belmont, CA, USA) at 10 min
intervals for 50 h. All microscope and camera controls were programmed through the
μManager software package (UCSF, San Francisco, CA, USA).51 Annotated time-
laps videos were created with the Fiji software package (NIH) for ImageJ.52
Cell detachment assay. Cells were seeded in 24-well plates, grown to 90%
confluency and treated with 8 or 16 μM of the PTP1B inhibitor, 10 μM of CPT or
DMSO as control in H14 media. After 24-h incubation, the medium was removed
and the cells were washed once with 1 × PBS and incubated with 0.25% trypsin at
37 °C for 1 min. In order to detach the cells from the culture plates, 1 × PBS with
10% FBS was added into the wells to inactivate the trypsin and the detached cells
were collected into tubes. The remaining cells were incubated with 0.25% trypsin for
20 min to detach all the cells and collected into fresh tubes. The cells were counted
and the data were presented as a percentage of cells detached after 1 min of
trypsin incubation to total cells.
Statistical analysis. All growth curves were performed in triplicate for
statistical accuracy. Graphs were created in Excel. Error bars represent the
standard deviation of the sample (S.D.). P-values below 0.05 were considered
significant (**P⩽ 0.01, *P⩽ 0.05).
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